# Cnicin

Cat. No.: HY-137984 CAS No.: 24394-09-0 Molecular Formula:  $C_{20}H_{26}O_{7}$ Molecular Weight: 378.42 SARS-CoV Target: Pathway: Anti-infection

-20°C, protect from light Storage:

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (264.26 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.6426 mL	13.2128 mL	26.4257 mL
	5 mM	0.5285 mL	2.6426 mL	5.2851 mL
	10 mM	0.2643 mL	1.3213 mL	2.6426 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.61 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.61 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.61 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description

Cnicin is a sesquiterpene lactone. Cnicin has antiproliferative effects, and induces cell death in primary myeloma cells. Cnicin also has anti-SARS-CoV-2 activity. Cnicin inhibits viral replication of SARS CoV-2 with an IC<sub>50</sub> of 1.18 µg/mL<sup>[1]</sup>.

### **REFERENCES**

[1]. Jöhrer K, et al. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target. J Mol Med (Berl). 2012 Jun;90(6):681-93.

2]. Alhadrami HA, et al. Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics. antibiotics (Basel). 2021 May 7;10(5):542.						
	Caution: Product has no	ot been fully validated for me	dical applications. For research use	only.		
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress			
		Deer Park Dr, Suite Q, Monmo				

Page 2 of 2 www.MedChemExpress.com